These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 32791194)
1. Synthesis and anti-cancer activity of bis-amino-phosphine ligand and its ruthenium(II) complexes. Engelbrecht Z; Roberts KE; Hussan A; Amenuvor G; Cronjé MJ; Darkwa J; Makhubela BCE; Sitole L Bioorg Med Chem Lett; 2020 Oct; 30(20):127492. PubMed ID: 32791194 [TBL] [Abstract][Full Text] [Related]
2. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents. Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686 [TBL] [Abstract][Full Text] [Related]
3. Ruthenium(II) Diphosphine Complexes with Mercapto Ligands That Inhibit Topoisomerase IB and Suppress Tumor Growth In Vivo. da Silva MM; Ribeiro GH; de Camargo MS; Ferreira AG; Ribeiro L; Barbosa MIF; Deflon VM; Castelli S; Desideri A; Corrêa RS; Ribeiro AB; Nicolella HD; Ozelin SD; Tavares DC; Batista AA Inorg Chem; 2021 Sep; 60(18):14174-14189. PubMed ID: 34477373 [TBL] [Abstract][Full Text] [Related]
4. Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes. Sathiya Kamatchi T; Mohamed Subarkhan MK; Ramesh R; Wang H; Małecki JG Dalton Trans; 2020 Aug; 49(32):11385-11395. PubMed ID: 32776042 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos. Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643 [TBL] [Abstract][Full Text] [Related]
6. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features. Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963 [TBL] [Abstract][Full Text] [Related]
7. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent. Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659 [TBL] [Abstract][Full Text] [Related]
8. New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action. Pavlović M; Nikolić S; Gligorijević N; Dojčinović B; Aranđelović S; Grgurić-Šipka S; Radulović S J Biol Inorg Chem; 2019 Mar; 24(2):297-310. PubMed ID: 30762123 [TBL] [Abstract][Full Text] [Related]
9. Exploring the potential of ruthenium(II)-phosphine-mercapto complexes as new anticancer agents. Palmeira-Mello MV; Costa AR; de Oliveira LP; Blacque O; Gasser G; Batista AA Dalton Trans; 2024 Jul; 53(26):10947-10960. PubMed ID: 38895770 [TBL] [Abstract][Full Text] [Related]
11. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7). Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726 [TBL] [Abstract][Full Text] [Related]
12. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug. Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828 [TBL] [Abstract][Full Text] [Related]
13. A nuclear permeable Ru(ii)-based photoactivated chemotherapeutic agent towards a series of cancer cells: in vitro and in vivo studies. Tian N; Feng Y; Sun W; Lu J; Lu S; Yao Y; Li C; Wang X; Zhou Q Dalton Trans; 2019 May; 48(19):6492-6500. PubMed ID: 30994660 [TBL] [Abstract][Full Text] [Related]
14. Probing the antibacterial and anticancer potential of tryptamine based mixed ligand Schiff base Ruthenium(III) complexes. Malik MA; Raza MK; Dar OA; Amadudin ; Abid M; Wani MY; Al-Bogami AS; Hashmi AA Bioorg Chem; 2019 Jun; 87():773-782. PubMed ID: 30974300 [TBL] [Abstract][Full Text] [Related]
17. Coumarin-modified ruthenium complexes: Synthesis, characterization, and antiproliferative activity against human cancer cells. Jakopec S; Hamzic LF; Bočkor L; Car I; Perić B; Kirin SI; Sedić M; Raić-Malić S Arch Pharm (Weinheim); 2024 Sep; 357(9):e2400271. PubMed ID: 38864840 [TBL] [Abstract][Full Text] [Related]
18. Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells. Tian M; Li J; Zhang S; Guo L; He X; Kong D; Zhang H; Liu Z Chem Commun (Camb); 2017 Nov; 53(95):12810-12813. PubMed ID: 29143019 [TBL] [Abstract][Full Text] [Related]